2020 Presentations
Thursday, February 13, 2020
Hematologic Malignancies
Indolent and aggressive non-Hodgkin Lymphoma including CAR-T cell therapy
Julie Vose
Myeloma status, including CAR-T Cell therapy
Sagar Lonial
AML and MDS: What’s new and exciting?
Brian Jonas
CLL: What’s on the horizon?
Susan O’Brien
Gastrointestinal Malignancies
Upper GI malignancies: Role of immunotherapy
Rachna Shroff
Lower GI: Colorectal cancer: Therapeutic options & future directions
Rachna Shroff
Friday, February 14, 2020
Melanoma, Skin Cancers, RCC
Melanoma and Skin Cancer: Past, present and future
Sanjiv Agarwala
RCC: Making sense of the options
Donald Trump
GU Cancers
Prostate Cancer: Androgen Disruption-2020
Donald Trump
Bladder Cancer: Where does immunotherapy stand today?
Ravi Madan
Lung/HNC
Debate Frontline Therapy for NSCLC PD1 alone / Combo: PD1 + Chemo Part 1
Luis Raez
Debate Frontline Therapy for NSCLC PD1 alone / Combo: PD1 + Chemo Part 2
Edgardo S. Santos Castillero
Saturday, February 15, 2020
Breast Cancer
De-escalating and escalating neoadjuvant therapy and implications for adjuvant treatment
George Sledge
Precision medicine meets breast oncology: Molecular testing to direct treatment decisions
William Gradishar
Triple negative breast cancer: new directions in immunotherapy and novel agents
Hope S. Rugo
What’s new for HER2+ disease?
Shanu Modi
Hormonal management of breast cancer
Joyce O’Shaughnessy
Role of genetic markers, risk and therapeutic choices
William Gradishar